Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group

Hepatitis C virus (HCV) has emerged as an important etiologic agent of liver injury and failure in patients infected with human immunodeficiency virus (HIV). The prevalence and characteristics of HCV in a representative cohort of HIV-infected patients have not been described. Therefore, a representa...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2002-03, Vol.34 (6), p.831-837
Main Authors: Sherman, Kenneth E., Rouster, Susan D., Chung, Raymond T., Rajicic, Natasa
Format: Article
Language:English
Subjects:
Adult
AIDS
AIDS-Related Opportunistic Infections - epidemiology
AIDS-Related Opportunistic Infections - virology
Biological and medical sciences
Clinical Trials as Topic
Coinfection
Cross-Sectional Studies
Female
Genotypes
Hemophilia
Hepacivirus
Hepacivirus - genetics
Hepacivirus - isolation & purification
Hepatitis C - blood
Hepatitis C - epidemiology
Hepatitis C - etiology
HIV
HIV Infections - blood
HIV Infections - complications
HIV/AIDS
Human viral diseases
Humans
Infections
Infectious diseases
Lymphocytes
Male
Medical sciences
Middle Aged
Prevalence
RNA
RNA, Viral - blood
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral hepatitis
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C virus (HCV) has emerged as an important etiologic agent of liver injury and failure in patients infected with human immunodeficiency virus (HIV). The prevalence and characteristics of HCV in a representative cohort of HIV-infected patients have not been described. Therefore, a representative sample of 1687 HIV-infected patients was studied; a 213-sample subcohort was selected by use of risk-based sampling from 2 large prospective US Adult AIDS Clinical Trials Group clinical trials. HCV prevalence, HCV RNA level, and genotype were determined. The weighted overall estimate of HCV prevalence in the study cohort was 16.1% (95% weighted confidence interval, 14.3%–17.8%), with significant variability depending on risk factors and HIV RNA levels. Among patients defined as being “at risk,” 72.7% were HCV positive, whereas, among low-risk patients, the positivity rate was 3.5%. Genotype 1 was found in 83.3% of infected patients. Median HCV RNA level was 6.08 × 106 IU/mL. High virus loads and genotype 1 prevalence may be important to interferon-based antiviral response rates among coinfected patients.
ISSN:1058-4838
1537-6591
DOI:10.1086/339042